Wednesday Sep 03, 2025
Ep. 15: Adapting to real life: how the MiniMed™ 780G system responds to glycemic variability
Explore how the MiniMed™ 780G system adapts in real time to life's messiness - and what the latest data reveals about its power to simplify even the most complicated days.
Product usage represented may not be approved or cleared in all markets.
*510k pending for Medtronic interoperable system; currently under review by FDA; not available for sale or distribution in the U.S.
Due to inherent data limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.
1. Tack CJ, et al. JMR Diabetes. 2018;3(4);e17 doi.org/10.2196/diabetes.
2. DiaTribeLearn. Making Sense of Diabetes. https://diatribe.org/diabetes-management/42-factors-affect-blood-glucose-surprising-update. Accessed Feb 28, 2025
3. Elhenawy YI, Kader MSA, Thabet RA. Diabetes Obes Metab. 2024 Nov;26(11):4916:4923. Doi:10.1111/dom.15891
4. Shin J et al. Significant Reduction in Real-world Nighttime Burden with the MiniMed(TM) 780G System. Poster presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, Florida.
5. McVean J et al. Hyperglycemia from Real-World Dawn Phenomenom is Nearly Eliminated with the MiniMed(TM) 780G system. Poster presented at: American Diabetes Association 84th Scientific Session; June 21-24, 2024; Orlando, Florida.
6. Tinti D., et al. Diabetes Obes Metab. 2025;1-4.
7. McVean, J et al. Stable glycemic control in or out of school in children using the MiniMed™ 780G system – a real-world study from Italy. Poster presented at ISPAD (International Society for Pediatric and Adolescent Diabetes). October 16-19, 2024; Lisobn, Portugal.
8. Elbarbary NS., Ismail EAR. Diabetes Research and Clinical Practice. 2025. https://doi.org/10.1016/j.diabres.2025.112042
9. Al-Sofiana ME., et al. Diabetes Obes Metab. 2023; 1-13.
The MiniMed™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 780G System includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Simplera Sync™ sensor can be used one time and has a life up to 6 days, followed by a grace period of 24 hours. During the grace period, the sensor will continue to work as it did during the first 6 days, to allow the patient to change their sensor more flexibly. However, some sensors may not survive the full wear period for a variety of reasons. Please be prepared to replace the sensor during the grace period to ensure sensor glucose values continue to be monitored.
The Simplera Sync™ sensor is not intended to be used directly to make therapy adjustments while the MiniMed 780G is operating in manual mode. All therapy adjustments in Manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Simplera Sync™ sensor. The Simplera Sync™ sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Simplera Sync™ sensor in the abdomen or other body sites, including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.
The Medtronic MiniMed™ 780G System consists of the following devices: MiniMed™ 780G Insulin Pump, Simplera Sync™ sensor, the Accu-Chek™Guide Link blood glucose meter, and the Accu-Chek™Guide Test Strips. The system requires a prescription from a healthcare professional.
WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.
WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with the system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library